Bicyclic compound and use thereof for medical purposes
US-10201520-B2 · Feb 12, 2019 · US
Bicyclic compound and use thereof for medical purposes
US10940134B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10940134-B2 |
| Application number | US-201916698432-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 27, 2019 |
| Priority date | Jul 28, 2009 |
| Publication date | Mar 9, 2021 |
| Grant date | Mar 9, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising the compound of formula (I): and a pharmaceutically acceptable solvent, wherein the composition is a parenteral solution.
Assignees
Inventors
Classifications
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
containing further heterocyclic ring systems · CPC title
Eye, e.g. artificial tears · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10940134B2 cover?
- Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., i…
- Who is the assignee on this patent?
- Ono Pharmaceutical Co
- What technology area does this patent fall under?
- Primary CPC classification C07D313/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).